Harrow Health (HROW) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-35814
Entity Registrant Name	Harrow Health, Inc.
Entity Central Index Key	0001360214
Entity Tax Identification Number	45-0567010
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	102 Woodmont Blvd.
Entity Address, Address Line Two	Suite 610
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37205
City Area Code	(615)
Local Phone Number	733-4730
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,121,997
Common Stock 0.001 Par Value Per Share [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	HROW
Security Exchange Name	NASDAQ
Sec8.625 Senior Notes Due 2026 [Member]
Title of 12(b) Security	8.625% Senior Notes due 2026
Trading Symbol	HROWL
Security Exchange Name	NASDAQ
Sec11.875 Senior Notes Due 2027 [Member]
Title of 12(b) Security	11.875% Senior Notes due 2027
Trading Symbol	HROWM
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 19,248,000	$ 96,270,000
Investment in Eton Pharmaceuticals	7,631,000	5,589,000
Accounts receivable, net	12,111,000	6,249,000
Inventories	9,093,000	6,541,000
Prepaid expenses and other current assets	3,604,000	3,611,000
Total current assets	51,687,000	118,260,000
Property, plant and equipment, net	3,586,000	3,486,000
Capitalized software costs, net	2,277,000	2,112,000
Deferred financing costs		1,950,000
Deferred tax asset	288,000
Operating lease right-of-use assets, net	7,336,000	7,513,000
Intangible assets, net	151,992,000	23,725,000
Goodwill	332,000	332,000
TOTAL ASSETS	217,498,000	157,378,000
Current liabilities
Accounts payable and accrued expenses	13,794,000	13,771,000
Accrued payroll and related liabilities	3,103,000	4,025,000
Deferred revenue and customer deposits	67,000	113,000
Current portion of operating lease obligations	744,000	723,000
Total current liabilities	17,708,000	18,632,000
Operating lease obligations, net of current portion	7,137,000	7,332,000
Accrued expenses, net of current portion	2,275,000
Notes payable, net of unamortized debt discount	168,850,000	104,174,000
TOTAL LIABILITIES	195,970,000	130,138,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 30,056,370 and 29,901,530 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	30,000	30,000
Additional paid-in capital	137,989,000	137,058,000
Accumulated deficit	(116,136,000)	(109,493,000)
TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY	21,883,000	27,595,000
Noncontrolling interests	(355,000)	(355,000)
TOTAL STOCKHOLDERS’ EQUITY	21,528,000	27,240,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 217,498,000	$ 157,378,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	30,056,370	29,901,530
Common stock, shares outstanding	30,056,370	29,901,530

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 26,103,000	$ 22,120,000
Cost of sales	(8,271,000)	(5,963,000)
Gross profit	17,832,000	16,157,000
Operating expenses:
Selling, general and administrative	15,888,000	13,398,000
Research and development	734,000	658,000
Total operating expenses	16,622,000	14,056,000
Income from operations	1,210,000	2,101,000
Other (expense) income:
Interest expense, net	(4,747,000)	(1,792,000)
Equity in losses of unconsolidated entities		(2,886,000)
Investment gain from Eton Pharmaceuticals	2,042,000	139,000
Loss on extinguishment of debt	(5,465,000)
Other income, net	29,000
Total other expense, net	(8,141,000)	(4,539,000)
Loss before income taxes	(6,931,000)	(2,438,000)
Income tax benefit	288,000
Net loss	$ (6,643,000)	$ (2,438,000)
Basic and diluted net loss per share of common stock	$ (0.22)	$ (0.09)
Weighted average number of shares of common stock outstanding, basic and diluted	30,289,730	27,226,819
Product Sales Net [Member]
Revenues:
Total revenues	$ 20,453,000	$ 20,340,000
Other Revenues [Member]
Revenues:
Total revenues	$ 5,650,000	$ 1,780,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Harrow Health, Inc. Stockholders' Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 27,000	$ 106,666,000	$ (95,407,000)	$ 11,286,000	$ (355,000)	$ 10,931,000
Beginning balance, shares at Dec. 31, 2021	26,902,763
Exercise of employee stock-based options		4,000		4,000		4,000
Exercise of employee stock-based options, shares	89,986
Vesting of RSUs	$ 1,000	(1,000)
Vesting of RSUs, shares	135,000
Shares withheld related to net share settlement of equity awards	$ (1,000)	(776,000)		(777,000)		(777,000)
Shares withheld related to net share settlement of equity awards, shares	(96,622)
Stock-based compensation expense		2,016,000		2,016,000		2,016,000
Net loss			(2,438,000)	(2,438,000)		(2,438,000)
Ending balance, value at Mar. 31, 2022	$ 27,000	107,909,000	(97,845,000)	10,091,000	(355,000)	9,736,000
Ending balance, shares at Mar. 31, 2022	27,031,127
Beginning balance, value at Dec. 31, 2022	$ 30,000	137,058,000	(109,493,000)	27,595,000	(355,000)	27,240,000
Beginning balance, shares at Dec. 31, 2022	29,901,530
Exercise of employee stock-based options		148,000		148,000		148,000
Exercise of employee stock-based options, shares	97,542
Vesting of RSUs
Vesting of RSUs, shares	111,000
Shares withheld related to net share settlement of equity awards		(850,000)		(850,000)		(850,000)
Shares withheld related to net share settlement of equity awards, shares	(53,702)
Stock-based compensation expense		1,633,000		1,633,000		1,633,000
Net loss			(6,643,000)	(6,643,000)		(6,643,000)
Ending balance, value at Mar. 31, 2023	$ 30,000	$ 137,989,000	$ (116,136,000)	$ 21,883,000	$ (355,000)	$ 21,528,000
Ending balance, shares at Mar. 31, 2023	30,056,370

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,643,000)	$ (2,438,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization of property, plant and equipment	292,000	419,000
Amortization of intangible assets	2,207,000	404,000
Amortization of operating lease right-of-use assets	177,000	124,000
Provision for bad debt expense	20,000	10,000
Amortization of debt issuance costs and debt discount	761,000	193,000
Investment gain from investment in Eton	(2,042,000)	(139,000)
Equity in losses of unconsolidated entities		2,886,000
Loss on extinguishment of debt	5,465,000
Stock-based compensation	1,633,000	2,016,000
Deferred taxes	(288,000)
Changes in assets and liabilities:
Accounts receivable	(5,882,000)	(1,535,000)
Inventories	(2,552,000)	(179,000)
Prepaid expenses and other current assets	7,000	(29,000)
Accounts payable and accrued expenses	(212,000)	369,000
Accrued payroll and related liabilities	(1,111,000)	(1,141,000)
Deferred revenue and customer deposits	(46,000)	7,000
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	(8,214,000)	967,000
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in patent and trademark assets		(6,000)
Purchase of product NDAs and patents	(130,474,000)
Purchases of property, plant and equipment	(496,000)	(404,000)
NET CASH USED IN INVESTING ACTIVITIES	(130,970,000)	(410,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations		(3,000)
Net proceeds from 11.875% notes payable, net of costs	4,961,000
Net proceeds from Oaktree loan, net of costs	61,585,000
Payment of taxes upon vesting of RSUs and exercise of stock options	(661,000)	(777,000)
Proceeds from exercise of stock options	148,000	4,000
Net proceeds from B Riley senior secured note, net of costs	55,879,000
Repayment of B. Riley senior secured note	(59,750,000)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	62,162,000	(776,000)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(77,022,000)	(219,000)
CASH AND CASH EQUIVALENTS, beginning of period	96,270,000	42,167,000
CASH AND CASH EQUIVALENTS, end of period	19,248,000	41,948,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	3,371,000	1,617,000
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property, plant and equipment included in accounts payable and accrued expenses	61,000
Right-of-use assets obtained in exchange for new operating lease obligations		1,036,000
Accrual of exit fee related to Oaktree Loan	2,275,000
Reclassification of derferred financing costs	1,950,000
Income taxes owed for exercise of stock options	$ 189,000

DESCRIPTION OF BUSINESS AND BAS

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. The Company owns non-controlling equity positions in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. The Company consolidates (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the three months ended March 31, 2023 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations. Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. The Company considers historical collection rates, the current financial status of its customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, the Company believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as the Company determined that the risk profile of its customers is consistent based on the type and industry in which they operate, mainly in the life sciences industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the life sciences industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. The accounts receivable balance on the Company’s condensed consolidated balance sheet as of March 31, 2023 was $ 12,111,000 82,000 SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2023 $ 73,000 Change in expected credit losses 20,000 Write-offs, net of recoveries (11,000 ) Balance at March 31, 2023 $ 82,000 Business Combinations and Asset Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Account Standards Board (“FASB”). Accounting Standards Codification (“ASC”) 805, Business Combinations Business Combinations The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligation for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the condensed consolidated statement of operations. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50 Business Combinations – Related Issues Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At March 31, 2023 and December 31, 2022, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities. As of March 31, 2023 and December 31, 2022, the fair market value of the Company’s investment in Eton was $ 7,631,000 5,589,000 The Company carries the 2026 Notes at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes are carried at face value less unamortized debt issuance costs, and the Oaktree Loan is carried at face value less the original issue discount and unamortized debt issuance costs on the condensed consolidated balance sheets and presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE March 31, 2023 December 31, 2022 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 72,628,000 $ 73,590,000 $ 72,436,000 $ 71,550,000 2027 Notes $ 36,900,000 $ 40,250,000 $ 31,738,000 $ 35,112,000 Oaktree Loan $ 59,322,000 $ 65,000,000 $ - $ - The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating and finance lease liabilities. The carrying amount of these financial instruments, except for operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating and finance lease liabilities approximate their respective fair values. Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs and warrants was 4,750,340 5,546,200 336,264 277,405 The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE 2023 2022 For the Three Months Ended March 31, 2023 2022 Numerator – net loss $ (6,643,000 ) $ (2,438,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 30,289,730 27,226,819 Net loss per share, basic and diluted $ (0.22 ) $ (0.09 ) Income Taxes The Company calculates its quarterly tax provision pursuant to the guidelines in ASC 740-270, Income Taxes The Company’s effective tax rate was 4.16 0 21 As of March 31, 2023 and December 31, 2022, there were no Investment in Eton Pharmaceuticals, Inc As of March 31, 2023, the Company owned 1,982,000 10 3.85 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities 2,042,000 139,000 7,631,000 5,589,000 Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 46 0 100 0 100 The following table summarizes the Company’s investments in Melt as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Paid-in-Kind In-substance Net Basis Method Losses Interest Capital Contributions Carrying value Common stock $ 5,810,000 $ (5,810,000 ) $ - $ $ - Loan 13,500,000 (13,500,000 ) 3,001,000 (3,001,000 ) - $ 19,310,000 $ (19,310,000 ) $ 3,001,000 $ (3,001,000 ) $ - See Note 5 for more information and related party disclosure regarding Melt. Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 20 0 The following table summarizes the Company’s investment in Surface as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Net Basis Method Losses Carrying value Common stock $ 5,320,000 $ (5,320,000 ) $ - See Note 6 for more information and related party disclosure regarding Surface. Recently Adopted Accounting Pronouncements In June 2016, FASB issued Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments

REVENUES

REVENUES	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
REVENUES	NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers Product Revenues The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s pharmacy services includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following: 1. Identify the contract(s) with a customer: 2. Identify the performance obligations in the contract: 3. Determine the transaction price: 4. Allocate the transaction price to the performance obligations in the contract: 5. Recognize revenue when (or as) the entity satisfies a performance obligation: Commission Revenues The Company had entered into an agreement whereby it was paid a fee calculated based on sales the Company generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement was recognized, at which point there was no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. Revenues From Transfer of Acquired Product Profit The Company entered into agreements whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic products from another pharmaceutical company (the “Seller”). During a temporary, transition period, the Seller continues Intellectual Property License Revenues The Company currently holds five intellectual property licenses and related agreements pursuant to which the Company has agreed to license or sell to a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time that the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source for the three months ended March 31, 2023 and 2022 consists of the following: SCHEDULE OF DISAGGREGATED REVENUE 2023 2022 For the Three Months Ended March 31, 2023 2022 Product sales, net $ 20,453,000 $ 20,340,000 Commission revenues - 1,320,000 Transfer of profits 5,650,000 460,000 Total revenues $ 26,103,000 $ 22,120,000 Deferred revenue and customer deposits at March 31, 2023 and December 31, 2022 were $ 67,000 113,000

RECENT PRODUCT ACQUISITIONS, LI

RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES	3 Months Ended
	Mar. 31, 2023
Recent Product Acquisitions Licenses And Divestitures
RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES	NOTE 4. RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES Acquisition of ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE In December 2022, the Company entered into an Asset Purchase Agreement (the “Fab 5 APA”) with Novartis Technology, LLC and Novartis Innovative Therapies AG (together, “Novartis”), pursuant to which the Company agreed to purchase from Novartis the exclusive commercial rights to assets associated with the following ophthalmic products (collectively the “Fab 5 Products”) in the U.S. (the “Fab 5 Acquisition”): ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE. Under the terms of the Fab 5 APA, the Company made a one-time payment of $ 130,000,000 45,000,000 The assets acquired in the Fab 5 Acquisition are identifiable intangible asset groups in similar asset classes and all directly related to the five product NDAs acquired. The developed technology is within one major intangible asset class. No workforce/employees were included in the Fab 5 Acquisition and the Company is required to utilize its own business inputs/processes to transfer and commercialize the Fab 5 Products and NDAs. As a result, the Company recognized this transaction as an asset acquisition. The Company incurred $ 558,000 130,000,000 130,558,000 Research and Development Divestiture of Non-Ophthalmic Assets In October 2022, wholly owned subsidiaries of the Company (“Imprimis”) entered into an Asset Purchase Agreement (the “RPC Agreement”) with Innovation Compounding Pharmacy, LLC (the “Buyer”). Under the terms of the RPC Agreement, Imprimis agreed to sell substantially all of its assets associated with its non-ophthalmology related compounding product line, including but not limited to, certain intellectual property rights, customer lists, databases, and formulations (the “RPC Assets”). The Buyer agreed to make offers of employment to six of the Company’s employees that were responsible for the sales activities associated with the RPC Assets. Under the terms of the RPC Agreement, the Buyer paid Imprimis an aggregate cash amount of $ 6,000,000 4,500,000 In connection with the RPC Agreement, Imprimis entered into a separate transition services agreement with the Buyer related to providing on going services associated with the RPC Assets, such as procuring and dispensing prescription orders, providing accounting and billing services and collecting accounts receivable. The Company expects Imprimis to provide transition services to the Buyer for up to six to nine months following the effective date of the RPC Agreement. The Company collected and will continue to collect cash on behalf of the Buyer for revenue generated by sales of RPC Assets from October 2022 through the transition period and the Company is obligated to transfer cash generated by such sales to the Buyer. The Company’s condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022 reflected $ 226,000 579,000 116,000 128,000 The amounts due from the Buyer for reimbursement of services performed under the transition services agreement was $ 162,000 254,000 307,000 453,000 124,000 94,800

INVESTMENT IN, AND NOTE RECEIVA

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS	NOTE 5. INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In February 2019, the Company and Melt entered into a Management Service Agreement between the Company and Melt (the “Melt MSA”), whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly amount of $ 10,000 During the three months ended March 31, 2023, the Company recorded $ 59,000 As of March 31, 2023, and December 31, 2022, the Company was due $ 198,000 139,000 The Company’s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during the year ended December 31, 2021. Mr. Baum re-joined the Melt board of directors in January 2023. At the time Mr. Baum re-joined, the Melt board of directors consists of five total board members, including Mr. Baum, who is the only representative of the Company on Melt’s board of directors. The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT 2023 2022 For the Three Months Ended March 31, 2023 2022 Revenues, net $ - $ - Loss from operations $ (1,858,000 ) $ (3,337,000 ) Net loss $ (1,858,000 ) $ (3,337,000 ) The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET At March 31, At December 31, 2023 2022 Current assets $ 133,000 $ 655,000 Non-current assets 133,000 107,000 Total assets $ 266,000 $ 762,000 Total liabilities $ 20,273,000 $ 19,056,000 Total preferred stock and stockholders’ deficit (20,007,000 ) (18,294,000 ) Total liabilities and stockholders’ equity $ 266,000 $ 762,000 Melt Note Receivable On September 1, 2021, the Company entered into a loan and security agreement in the principal amount of $ 13,500,000 12.50 10,000,000 Melt has granted the Company a security interest in substantially all of its personal property, rights and assets, including intellectual property rights, to secure the payment of all amounts owed under the Melt Loan Agreement. The Melt Loan Agreement contains customary representations, warranties and covenants, including covenants by Melt limiting additional indebtedness, liens, mergers and acquisitions, dispositions, investments, distributions, subordinated debt, and transactions with affiliates. The Melt Loan Agreement includes customary events of default, and upon the occurrence of an event of default (subject to cure periods for certain events of default), all amounts owed by Melt thereunder may be declared immediately due and payable by the Company, and the interest rate on the loan may be increased by 3 In connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt’s drug candidates for a period of five years following the effective date of the Melt Loan Agreement. The net funds received by Melt excluded $ 908,000 16,501,000 15,984,000 Investments – Equity Method and Joint Ventures

INVESTMENT IN SURFACE OPHTHALMI

INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2023
Investment In Surface Ophthalmics Inc. - Related Party Transactions
INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS	NOTE 6. INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding. As of March 31, 2023, the Company owned 3,500,000 The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT 2023 2022 For the Three Months Ended March 31, 2023 2022 Revenues, net $ - $ - Loss from operations $ (1,587,000 ) $ (1,996,000 ) Net loss $ (1,524,000 ) $ 1,996,000 The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET At March 31, At December 31, 2023 2022 Current assets $ 13,350,000 $ 15,350,000 Non-current assets 902,000 652,000 Total assets $ 14,252,000 $ 16,002,000 Total liabilities $ 995,000 $ 1,586,000 Total preferred stock and stockholders’ deficit 13,257,000 14,416,000 Total liabilities and stockholders’ equity $ 14,252,000 $ 16,002,000

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 7. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded commercial pharmaceutical products, including those held at a 3PL, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2023 and December 31, 2022 was as follows: SCHEDULE OF INVENTORIES March 31, 2023 December 31, 2022 Raw materials $ 5,023,000 $ 3,707,000 Work in progress 36,000 38,000 Finished goods 4,034,000 2,796,000 Total inventories $ 9,093,000 $ 6,541,000

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 8. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid insurance $ 527,000 $ 858,000 Prepaid computer software licenses and related expenses 1,072,000 1,165,000 Due from Melt Pharmaceuticals 198,000 139,000 Other prepaid expenses 1,689,000 1,331,000 Deposits and other current assets 118,000 118,000 Total prepaid expenses and other current assets $ 3,604,000 $ 3,611,000

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 9. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT March 31, 2023 December 31, 2021 Property, plant and equipment, net: Computer hardware $ 1,060,000 $ 979,000 Furniture and equipment 922,000 860,000 Lab and pharmacy equipment 4,335,000 4,259,000 Leasehold improvements 6,555,000 6,449,000 Property, plant and equipment, gross 12,872,000 12,547,000 Accumulated depreciation (9,286,000 ) (9,061,000 ) Property, plant and equipment, net $ 3,586,000 $ 3,486,000 For the three months ended March 31, 2023 and 2022, depreciation expense related to the property, plant and equipment was $ 225,000 376,000

CAPITALIZED SOFTWARE DEVELOPMEN

CAPITALIZED SOFTWARE DEVELOPMENT COSTS	3 Months Ended
	Mar. 31, 2023
Capitalized Software Development Costs
CAPITALIZED SOFTWARE DEVELOPMENT COSTS	NOTE 10. CAPITALIZED SOFTWARE DEVELOPMENT COSTS Capitalized software development costs at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS March 31, 2023 December 31, 2022 Capitalized internal-use software development costs $ 1,415,000 $ 1,413,000 Acquired third-party software license for internal-use 159,000 159,000 Total gross capitalized software for internal-use 1,574,000 1,572,000 Accumulated amortization (860,000 ) (793,000 ) Capitalized internal-use software in process 1,563,000 1,333,000 Total finite lived intangible assets net $ 2,277,000 $ 2,112,000 The Company recorded amortization expense of $ 67,000 43,000

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	NOTE 11. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at March 31, 2023 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS Amortization Periods (in years) Cost Accumulated Amortization Impairment Net Carrying Value Patents 7 19 $ 981,000 $ (183,000 ) $ - $ 798,000 Licenses 20 100,000 (25,000 ) - 75,000 Trademarks Indefinite 267,000 - - 267,000 Acquired NDAs 10 15 154,193,000 (3,533,000 ) - 150,660,000 Customer relationships 3 15 596,000 (475,000 ) - 121,000 Trade name 5 75,000 (5,000 ) - 70,000 Non-competition clause 3 4 50,000 (50,000 ) - - State pharmacy licenses 25 8,000 (7,000 ) - 1,000 $ 156,270,000 $ (4,278,000 ) $ - $ 151,992,000 Amortization expense for intangible assets for the three months ended March 31, 2023 and 2022 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS 2023 2022 For the Three Months Ended March 31, 2023 2022 Patents $ 22,000 $ 22,000 Licenses 2,000 8,000 Acquired NDAs 2,170,000 341,000 Customer relationships 13,000 33,000 Amortization of intangible assets $ 2,207,000 $ 404,000 Estimated future amortization expense for the Company’s intangible assets at March 31, 2023 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE Remainder of 2023 $ 8,777,000 2024 11,673,000 2025 11,652,000 2026 11,652,000 2027 11,652,000 Thereafter 96,319,000 Intangible assets $ 151,725,000

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES 2023 2022 March 31, December 31, 2023 2022 Accounts payable $ 6,237,000 $ 6,440,000 Accrued insurance premium 237,000 575,000 Accrued IHEEZO milestone payment (see Note 16) 5,000,000 5,000,000 Accrued RPC transition payments (see Note 4) 307,000 453,000 Accrued litigation settlements 49,000 49,000 Accrued exit fee for note payable (see Note 13) 2,275,000 - Accrued interest 1,964,000 1,254,000 Total accounts payable and accrued expenses $ 16,069,000 $ 13,771,000 Less: Current portion (13,794,000 ) (13,771,000 ) Non-current total accrued expenses $ 2,275,000 $ - The Company financed all insurance policies for the policy term of August 17, 2022 through August 16, 2023. The financing agreement has an interest rate of 4.13 114,000

DEBT

DEBT	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 13. DEBT Oaktree Loan In March 2023, the Company entered into a Credit and Guaranty Agreement (the “Oaktree Loan”) with Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “Oaktree”), providing for a senior secured term loan facility to the Company with a principal amount of up to $ 100,000,000 65,000,000 B. Riley Loan and Security Agreement – Paid in Full 35,000,000 30,000,000 The Oaktree Loan is secured by nearly all of the assets, including intellectual property, of the Company and its material subsidiaries. The Oaktree Loan which has a maturity date of January 19, 2026 6.5 11.398 915,000 2,500,000 3.50 2,275,000 5,690,000 The Oaktree Loan contains customary guarantees and covenants, including financial covenants related to minimum liquidity and minimum net revenues. As of the end of the fiscal quarter ending December 31, 2024, if the Company’s Total Leverage Ratio (as defined in the Oaktree Loan) is greater than or equal to five times, but less than seven times, the Company will be required to issue to Oaktree warrants to purchase 375,000 375,000 750,000 Interest expense related to the Oaktree Loan totaled $ 95,000 12,000 HROWM - 11.875% Senior Notes Due 2027 In December 2022 and in January 2023, the Company closed an offering of $ 35,000,000 5,250,000 11.875 25.00 36,699,000 3,551,000 The 2027 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of the Company’s other existing and future senior unsecured and unsubordinated indebtedness. The 2027 Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The 2027 Notes bear interest at the rate of 11.875 December 31, 2027 At any time prior to December 31, 2024, the Company may, at its option, redeem the 2027 Notes, in whole at any time or in part from time to time, at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2027 Notes for cash in whole or in part at any time at its option (i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note Interest expense related to the 2027 Notes totaled $ 1,395,000 200,000 Our Chief Executive Officer, Mark L. Baum, Chief Financial Officer, Andrew R. Boll along with directors Dr. Richard Lindstrom and R. Lawrence Van Horn, in aggregate, own $ 950,000 HROWL - 8.625% Senior Notes Due 2026 In April 2021, the Company closed an offering of $ 50,000,000 5,000,000 25.00 51,909,000 3,091,000 20,000,000 25.75 278,000 19,164,000 1,158,000 322,000 The 2026 Notes 8.625 April 30, 2026 issuance costs were recorded as a debt discount and are being amortized as interest expense, net of the amortization of the premium on note issuance, over the term of the 2026 Notes using the effective interest rate method. Prior to February 1, 2026, the Company may, at its option, redeem the 2026 Notes, in whole at any time or in part from time to time, at a redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed Interest expense related to the 2026 Notes totaled $ 1,810,000 1,810,000 193,000 193,000 On December 14, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “BR Loan”) with B. Riley Commercial Capital, LLC, as Administrative Agent for the Lenders. The BR Loan provided for a loan facility of up to $ 100,000,000 December 14, 2025 10.875 The BR Loan was secured by an intellectual property security agreement entered into in connection with the BR Loan, and by all assets of the Company and its material subsidiaries. The outstanding balance of the BR Loan was due in full on the maturity date. The BR Loan provided for voluntary prepayment subject to no prepayment fee if no loan had been funded or the prepayment or repayment occured (other than as a result of acceleration of the BR Loan) on or prior to the date that was 90 days following the Effective Date and up to 3.00 In January 2023, $ 59,750,000 1,200,000 Interest expense related to the BR Loan totaled $ 1,565,000 356,000 5,465,000 At March 31, 2023, future minimum payments under the Company’s debt are as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES Amount Remainder of 2023 $ 14,145,000 2024 18,695,000 2025 18,695,000 2026 147,325,000 2027 45,030,000 Total minimum payments 243,890,000 Less: amount representing interest payments (63,640,000 ) Notes payable, gross 180,250,000 Less: unamortized discount, net of premium (11,400,000 ) Notes payable, net of unamortized discount $ 168,850,000

LEASES

LEASES	3 Months Ended
	Mar. 31, 2023
Leases
LEASES	NOTE 14. LEASES The Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining terms between one five years ● An operating lease for 5,789 March 2025 ● An operating lease for 35,326 July 2026 1,400 8,900 ● An operating lease for 5,500 November 30, 2024 ● An operating lease for 11,552 June 2027 At March 31, 2023, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 6.61 10.72 During the three months ended March 31, 2023 and 2022, cash paid for amounts included for the operating lease liabilities was $ 306,000 166,000 309,000 238,000 Future lease payments under operating leases as of March 31, 2023 were as follows : SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES Operating Leases Remainder of 2023 $ 925,000 2024 1,262,000 2025 1,093,000 2026 1,114,000 2027 972,000 Thereafter 5,829,000 Total minimum lease payments 11,195,000 Less: amount representing interest payments (3,314,000 ) Total operating lease liabilities 7,881,000 Less: current portion, operating lease liabilities (744,000 ) Operating lease liabilities, net of current portion $ 7,137,000

STOCKHOLDERS_ EQUITY AND STOCK-

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION	NOTE 15. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Common Stock During the three months ended March 31, 2023, the Company issued 33,063 148,000 33,063 3.50 7.60 During the three months ended March 31, 2023, 23,000 13,398 9,602 142,000 During the three months ended March 31, 2023, 88,000 52,821 35,179 519,000 During the three months ended March 31, 2023, the Company issued 55,558 90,000 6.00 25,521 8,921 189,000 During the three months ended March 31, 2023, 16,405 Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan; however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of March 31, 2023, the 2017 Plan provides for the issuance of a maximum of 6,000,000 shares of the Company’s common stock. The purposes of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had 2,145,767 Stock Options A summary of stock option activity under the Plans for the three months ended March 31, 2023 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Options outstanding – January 1, 2022 3,027,701 $ 5.90 Options granted 28,500 $ 17.40 Options exercised (123,063 ) $ 5.54 Options cancelled/forfeited (42,112 ) $ 5.61 Options outstanding – March 31, 2023 2,891,026 $ 6.03 4.30 $ 43,730,000 Options exercisable 2,589,182 $ 5.73 3.77 $ 39,941,000 Options vested and expected to vest 2,848,713 $ 5.99 4.23 $ 43,219,000 The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise price lower than the market price on March 31, 2023, based on the closing price of the Company’s common stock of $ 21.16 During the three months ended March 31, 2023, the Company granted stock options to certain employees. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of ten years. Vesting terms for options granted to employees during the three months ended March 31, 2023 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10 The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2023 Weighted-average fair value of options granted $ 10.58 Expected terms (in years) 5.50 6.11 Expected volatility 69 70 % Risk-free interest rate 3.64 3.76 % Dividend yield - The following table summarizes information about stock options outstanding and exercisable at March 31, 2023: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.47 1.73 298,112 4.71 $ 1.72 298,112 $ 1.72 $ 2.23 2.60 309,068 3.61 $ 2.26 309,068 $ 2.26 $ 3.95 310,000 2.93 $ 3.95 310,000 $ 3.95 $ 4.08 6.30 409,850 5.66 $ 5.99 398,194 $ 6.00 $ 6.75 7.30 402,000 7.43 $ 7.18 279,500 $ 7.29 $ 7.37 7.79 260,323 5.13 $ 7.53 166,760 $ 7.50 $ 7.87 600,000 2.33 $ 7.87 600,000 $ 7.87 $ 7.89 12.38 274,173 2.57 $ 9.12 227,548 $ 8.84 $ 15.17 7,500 9.84 $ 15.17 - $ - $ 18.35 20,000 9.82 $ 18.35 - $ - $ 1.47 18.35 2,891,026 4.30 $ 6.03 2,589,182 $ 5.73 As of March 31, 2023, there was approximately $ 1,441,000 3.0 341,000 272,000 The intrinsic value of options exercised during the three months ended March 31, 2023 was $ 1,819,000 Restricted Stock Units/Performance Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. A summary of the Company’s RSU activity (including performance stock units) and related information for the three months ended March 31, 2023 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY Number of RSUs Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2023 2,061,719 $ 6.88 RSUs granted - $ - RSUs vested (127,405 ) $ 7.34 RSUs cancelled/forfeited (75,000 ) $ 5.83 RSUs unvested - March 31, 2023 1,859,314 $ 6.82 As of March 31, 2023, the total unrecognized compensation expense related to unvested RSUs was approximately $ 2,476,000 0.4 1,292,000 1,744,000 Stock-Based Compensation Summary The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS 2023 2022 For the Three Months Ended March 31, 2023 2022 Employees - selling, general and administrative $ 1,328,000 $ 1,676,000 Employees - R&D 163,000 186,000 Directors - selling, general and administrative 125,000 100,000 Consultants - R&D 17,000 54,000 Total $ 1,633,000 $ 2,016,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16. COMMITMENTS AND CONTINGENCIES Legal General and Other In the ordinary course of business, the Company is involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. The Company describes legal proceedings and other matters that are/were significant or that it believes could become significant in this footnote. The Company records accruals for loss contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of a liability that has been accrued previously. The Company’s legal proceedings involve various aspects of its business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. Typically, a number of the matters pending against the Company are at early stages of the legal process, which in complex proceedings of the sort the Company face often extend for several years. While it is not possible to accurately predict or determine the eventual outcomes of matters that have not concluded, an adverse determination in one or more of matter (whether discussed in this footnote or not) currently pending may have a material adverse effect on the Company’s condensed consolidated results of operations, financial position or cash flows. Ocular Science, Inc. et. al In July 2021, ImprimisRx, LLC, a subsidiary of the Company, filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. (together, “OSRX”) in the U.S. District Court for the Southern District of California, asserting claims for copyright infringement, trademark infringement, unfair competition and false advertising (Lanham Act). ImprimisRx is seeking damages from OSRX. Since July 2021, the complaint has been amended and OSRX added counterclaims alleging ImprimisRx, LLC is violating the Lanham Act with false advertising. Both parties are seeking damages from the other. Discovery is currently ongoing and trial is set to take place in the fourth quarter of 2023. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. Indemnities In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company indemnifies Oaktree for certain claims and losses associated with the Oaktree Loan. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Klarity License Agreement – Related Party The Company entered into a license agreement in April 2017, as amended in April 2018 (the “Klarity License Agreement”), with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”). Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. 50,000 50,000 50,000 50,000 100,000 71,000 30,000 75,000 71,000 Injectable Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”). Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold 33,000 9,000 8,000 8,000 7,000 Other Asset Purchase, License and Related Agreements The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (i) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (ii) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (iii) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. During the three months ended March 31, 2023 and 2022, $ 293,000 213,000 Sintetica Agreement In July 2021, the Company entered into a License and Supply Agreement (the “Sintetica Agreement”) with Sintetica S.A. (“Sintetica”), pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate (“IHEEZO”) in the U.S. and Canada. Pursuant to the Sintetica Agreement, the Company agreed to pay Sintetica a per unit transfer price to supply IHEEZO, along with a per unit royalty for units sold. The Company is required to pay Sintetica up to $ 18,000,000 5,000,000 5,000,000 Subject to certain limitations, the Sintetica Agreement has a ten-year term, and allows for a ten-year extension if certain sales thresholds are met. Wakamoto Agreement In August 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement (together, the “Wakamoto Agreements”) with Wakamoto Pharmaceutical Co., Ltd. (“Wakamoto”), pursuant to which Wakamoto granted the Company the exclusive license and marketing rights to its ophthalmic drug candidate (“MAQ-100”) in the U.S. and Canada. Pursuant to the Wakamoto 2,000,000 6,200,000 Subject to certain limitations, the term of the Agreements is for five years from the date of the FDA’s market approval of MAQ-100 and allows for a five-year extension if certain unit sales thresholds are met. Eyepoint Commercial Alliance Agreement - Terminated In August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU ® Pursuant to the Dexycu Agreement Dexycu Agreement Following the preliminary Hospital Outpatient Prospective Payment System (HOPPS) rule proposed by the Centers for Medicare & Medicaid Services (CMS) in July of 2022, which did not contain an extension of the pass-through payment period for Dexycu beyond December 31, 2022, the Company entered into a Mutual Termination Agreement (the “Termination Agreement”) with Eyepoint on October 7, 2022, pursuant to which Eyepoint and the Company agreed (a) that the Company will continue to support the sale of Dexycu through the fourth quarter of 2022, consistent with the Company’s level of effort during the January through June 2022 period, (b) to decrease the required minimum quarterly sales levels based on Dexycu unit demand for the fourth quarter of 2022, and (c) to terminate the Dexycu Agreement, along with ancillary letter agreements, effective January 1, 2023. During the three months ended March 31, 2022, the Company recorded $ 1,320,000 Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and marketing representation services to Harrow in select geographies in the U.S. in connection with the Company’s ophthalmic pharmaceutical compounded formulations or related products. Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts Commission expenses of $ 130,000 1,047,000

SEGMENTS AND CONCENTRATIONS

SEGMENTS AND CONCENTRATIONS	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
SEGMENTS AND CONCENTRATIONS	NOTE 17. SEGMENTS AND CONCENTRATIONS The Company operates its business on the basis of a single reportable segment, which is the business of discovery, development, and commercialization of innovative ophthalmic therapies The Company has two products that each comprised more than 10% of total revenues during the three months ended March 31, 2023 and 2022. These products collectively accounted for 36 32 The Company sells its products and compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total product sales during the three months ended March 31, 2023 and 2022. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 90 74

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to March 31, 2023 through the filing date of this Quarterly Report on Form 10-Q. Based on its evaluation, no events other than those described below need to be disclosed. In April 2023, the Company issued 62,367 180,000 8.99 77,167 40,466 849,000 In April 2023, the Company issued 3,260 3,260 1.70 7.52 In April 2023, the Company granted 1,567,913 25 50 SCHEDULE OF SHARE BASED COMPENSATION Tranche Number of Shares Target Share Price Tranche 1 223,988 $25 Tranche 2 335,981 $35 Tranche 3 447,975 $45 Tranche 4 559,969 $50

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Risks, Uncertainties and Liquidity	Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.
Credit Losses	Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. The Company considers historical collection rates, the current financial status of its customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, the Company believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as the Company determined that the risk profile of its customers is consistent based on the type and industry in which they operate, mainly in the life sciences industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the life sciences industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. The accounts receivable balance on the Company’s condensed consolidated balance sheet as of March 31, 2023 was $ 12,111,000 82,000 SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2023 $ 73,000 Change in expected credit losses 20,000 Write-offs, net of recoveries (11,000 ) Balance at March 31, 2023 $ 82,000
Business Combinations and Asset Acquisitions	Business Combinations and Asset Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Account Standards Board (“FASB”). Accounting Standards Codification (“ASC”) 805, Business Combinations Business Combinations The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligation for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the condensed consolidated statement of operations. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50 Business Combinations – Related Issues
Fair Value Measurements	Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At March 31, 2023 and December 31, 2022, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities. As of March 31, 2023 and December 31, 2022, the fair market value of the Company’s investment in Eton was $ 7,631,000 5,589,000 The Company carries the 2026 Notes at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes are carried at face value less unamortized debt issuance costs, and the Oaktree Loan is carried at face value less the original issue discount and unamortized debt issuance costs on the condensed consolidated balance sheets and presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE March 31, 2023 December 31, 2022 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 72,628,000 $ 73,590,000 $ 72,436,000 $ 71,550,000 2027 Notes $ 36,900,000 $ 40,250,000 $ 31,738,000 $ 35,112,000 Oaktree Loan $ 59,322,000 $ 65,000,000 $ - $ - The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating and finance lease liabilities. The carrying amount of these financial instruments, except for operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating and finance lease liabilities approximate their respective fair values.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs and warrants was 4,750,340 5,546,200 336,264 277,405 The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE 2023 2022 For the Three Months Ended March 31, 2023 2022 Numerator – net loss $ (6,643,000 ) $ (2,438,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 30,289,730 27,226,819 Net loss per share, basic and diluted $ (0.22 ) $ (0.09 )
Income Taxes	Income Taxes The Company calculates its quarterly tax provision pursuant to the guidelines in ASC 740-270, Income Taxes The Company’s effective tax rate was 4.16 0 21 As of March 31, 2023 and December 31, 2022, there were no
Investment in Eton Pharmaceuticals, Inc	Investment in Eton Pharmaceuticals, Inc As of March 31, 2023, the Company owned 1,982,000 10 3.85 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities 2,042,000 139,000 7,631,000 5,589,000
Investment in Melt Pharmaceuticals, Inc. – Related Party	Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 46 0 100 0 100 The following table summarizes the Company’s investments in Melt as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Paid-in-Kind In-substance Net Basis Method Losses Interest Capital Contributions Carrying value Common stock $ 5,810,000 $ (5,810,000 ) $ - $ $ - Loan 13,500,000 (13,500,000 ) 3,001,000 (3,001,000 ) - $ 19,310,000 $ (19,310,000 ) $ 3,001,000 $ (3,001,000 ) $ - See Note 5 for more information and related party disclosure regarding Melt.
Investment in Surface Ophthalmics, Inc. – Related Party	Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 20 0 The following table summarizes the Company’s investment in Surface as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Net Basis Method Losses Carrying value Common stock $ 5,320,000 $ (5,320,000 ) $ - See Note 6 for more information and related party disclosure regarding Surface.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, FASB issued Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2023
SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS	SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2023 $ 73,000 Change in expected credit losses 20,000 Write-offs, net of recoveries (11,000 ) Balance at March 31, 2023 $ 82,000
SCHEDULE OF ESTIMATED FAIR VALUE	The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE March 31, 2023 December 31, 2022 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 72,628,000 $ 73,590,000 $ 72,436,000 $ 71,550,000 2027 Notes $ 36,900,000 $ 40,250,000 $ 31,738,000 $ 35,112,000 Oaktree Loan $ 59,322,000 $ 65,000,000 $ - $ -
SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE	The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE 2023 2022 For the Three Months Ended March 31, 2023 2022 Numerator – net loss $ (6,643,000 ) $ (2,438,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 30,289,730 27,226,819 Net loss per share, basic and diluted $ (0.22 ) $ (0.09 )
Melt Pharmaceuticals, Inc. [Member]
SCHEDULE OF INVESTMENT	The following table summarizes the Company’s investments in Melt as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Paid-in-Kind In-substance Net Basis Method Losses Interest Capital Contributions Carrying value Common stock $ 5,810,000 $ (5,810,000 ) $ - $ $ - Loan 13,500,000 (13,500,000 ) 3,001,000 (3,001,000 ) - $ 19,310,000 $ (19,310,000 ) $ 3,001,000 $ (3,001,000 ) $ -
Surface Ophthalmics Inc [Member]
SCHEDULE OF INVESTMENT	The following table summarizes the Company’s investment in Surface as of March 31, 2023: SCHEDULE OF INVESTMENT Cost Share of Equity Net Basis Method Losses Carrying value Common stock $ 5,320,000 $ (5,320,000 ) $ -

REVENUES (Tables)

REVENUES (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
SCHEDULE OF DISAGGREGATED REVENUE	Revenue disaggregated by revenue source for the three months ended March 31, 2023 and 2022 consists of the following: SCHEDULE OF DISAGGREGATED REVENUE 2023 2022 For the Three Months Ended March 31, 2023 2022 Product sales, net $ 20,453,000 $ 20,340,000 Commission revenues - 1,320,000 Transfer of profits 5,650,000 460,000 Total revenues $ 26,103,000 $ 22,120,000

INVESTMENT IN, AND NOTE RECEI_2

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF CONDENSED INCOME STATEMENT	The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT 2023 2022 For the Three Months Ended March 31, 2023 2022 Revenues, net $ - $ - Loss from operations $ (1,858,000 ) $ (3,337,000 ) Net loss $ (1,858,000 ) $ (3,337,000 )
SCHEDULE OF CONDENSED BALANCE SHEET	The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET At March 31, At December 31, 2023 2022 Current assets $ 133,000 $ 655,000 Non-current assets 133,000 107,000 Total assets $ 266,000 $ 762,000 Total liabilities $ 20,273,000 $ 19,056,000 Total preferred stock and stockholders’ deficit (20,007,000 ) (18,294,000 ) Total liabilities and stockholders’ equity $ 266,000 $ 762,000

INVESTMENT IN SURFACE OPHTHAL_2

INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2023
Investment In Surface Ophthalmics Inc. - Related Party Transactions
SUMMARY OF CONDENSED INCOME STATEMENT	The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT 2023 2022 For the Three Months Ended March 31, 2023 2022 Revenues, net $ - $ - Loss from operations $ (1,587,000 ) $ (1,996,000 ) Net loss $ (1,524,000 ) $ 1,996,000
SUMMARY OF CONDENSED BALANCE SHEET	The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET At March 31, At December 31, 2023 2022 Current assets $ 13,350,000 $ 15,350,000 Non-current assets 902,000 652,000 Total assets $ 14,252,000 $ 16,002,000 Total liabilities $ 995,000 $ 1,586,000 Total preferred stock and stockholders’ deficit 13,257,000 14,416,000 Total liabilities and stockholders’ equity $ 14,252,000 $ 16,002,000

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES March 31, 2023 December 31, 2022 Raw materials $ 5,023,000 $ 3,707,000 Work in progress 36,000 38,000 Finished goods 4,034,000 2,796,000 Total inventories $ 9,093,000 $ 6,541,000

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid insurance $ 527,000 $ 858,000 Prepaid computer software licenses and related expenses 1,072,000 1,165,000 Due from Melt Pharmaceuticals 198,000 139,000 Other prepaid expenses 1,689,000 1,331,000 Deposits and other current assets 118,000 118,000 Total prepaid expenses and other current assets $ 3,604,000 $ 3,611,000

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT March 31, 2023 December 31, 2021 Property, plant and equipment, net: Computer hardware $ 1,060,000 $ 979,000 Furniture and equipment 922,000 860,000 Lab and pharmacy equipment 4,335,000 4,259,000 Leasehold improvements 6,555,000 6,449,000 Property, plant and equipment, gross 12,872,000 12,547,000 Accumulated depreciation (9,286,000 ) (9,061,000 ) Property, plant and equipment, net $ 3,586,000 $ 3,486,000

CAPITALIZED SOFTWARE DEVELOPM_2

CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)	3 Months Ended
	Mar. 31, 2023
Capitalized Software Development Costs
SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS	Capitalized software development costs at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS March 31, 2023 December 31, 2022 Capitalized internal-use software development costs $ 1,415,000 $ 1,413,000 Acquired third-party software license for internal-use 159,000 159,000 Total gross capitalized software for internal-use 1,574,000 1,572,000 Accumulated amortization (860,000 ) (793,000 ) Capitalized internal-use software in process 1,563,000 1,333,000 Total finite lived intangible assets net $ 2,277,000 $ 2,112,000

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The Company’s intangible assets at March 31, 2023 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS Amortization Periods (in years) Cost Accumulated Amortization Impairment Net Carrying Value Patents 7 19 $ 981,000 $ (183,000 ) $ - $ 798,000 Licenses 20 100,000 (25,000 ) - 75,000 Trademarks Indefinite 267,000 - - 267,000 Acquired NDAs 10 15 154,193,000 (3,533,000 ) - 150,660,000 Customer relationships 3 15 596,000 (475,000 ) - 121,000 Trade name 5 75,000 (5,000 ) - 70,000 Non-competition clause 3 4 50,000 (50,000 ) - - State pharmacy licenses 25 8,000 (7,000 ) - 1,000 $ 156,270,000 $ (4,278,000 ) $ - $ 151,992,000
SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS	Amortization expense for intangible assets for the three months ended March 31, 2023 and 2022 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS 2023 2022 For the Three Months Ended March 31, 2023 2022 Patents $ 22,000 $ 22,000 Licenses 2,000 8,000 Acquired NDAs 2,170,000 341,000 Customer relationships 13,000 33,000 Amortization of intangible assets $ 2,207,000 $ 404,000
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE	Estimated future amortization expense for the Company’s intangible assets at March 31, 2023 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE Remainder of 2023 $ 8,777,000 2024 11,673,000 2025 11,652,000 2026 11,652,000 2027 11,652,000 Thereafter 96,319,000 Intangible assets $ 151,725,000

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	Accounts payable and accrued expenses at March 31, 2023 and December 31, 2022 consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES 2023 2022 March 31, December 31, 2023 2022 Accounts payable $ 6,237,000 $ 6,440,000 Accrued insurance premium 237,000 575,000 Accrued IHEEZO milestone payment (see Note 16) 5,000,000 5,000,000 Accrued RPC transition payments (see Note 4) 307,000 453,000 Accrued litigation settlements 49,000 49,000 Accrued exit fee for note payable (see Note 13) 2,275,000 - Accrued interest 1,964,000 1,254,000 Total accounts payable and accrued expenses $ 16,069,000 $ 13,771,000 Less: Current portion (13,794,000 ) (13,771,000 ) Non-current total accrued expenses $ 2,275,000 $ -

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES	At March 31, 2023, future minimum payments under the Company’s debt are as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES Amount Remainder of 2023 $ 14,145,000 2024 18,695,000 2025 18,695,000 2026 147,325,000 2027 45,030,000 Total minimum payments 243,890,000 Less: amount representing interest payments (63,640,000 ) Notes payable, gross 180,250,000 Less: unamortized discount, net of premium (11,400,000 ) Notes payable, net of unamortized discount $ 168,850,000

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2023
Leases
SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES	Future lease payments under operating leases as of March 31, 2023 were as follows : SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES Operating Leases Remainder of 2023 $ 925,000 2024 1,262,000 2025 1,093,000 2026 1,114,000 2027 972,000 Thereafter 5,829,000 Total minimum lease payments 11,195,000 Less: amount representing interest payments (3,314,000 ) Total operating lease liabilities 7,881,000 Less: current portion, operating lease liabilities (744,000 ) Operating lease liabilities, net of current portion $ 7,137,000

STOCKHOLDERS_ EQUITY AND STOC_2

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SCHEDULE OF STOCK OPTION PLAN ACTIVITY	A summary of stock option activity under the Plans for the three months ended March 31, 2023 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Options outstanding – January 1, 2022 3,027,701 $ 5.90 Options granted 28,500 $ 17.40 Options exercised (123,063 ) $ 5.54 Options cancelled/forfeited (42,112 ) $ 5.61 Options outstanding – March 31, 2023 2,891,026 $ 6.03 4.30 $ 43,730,000 Options exercisable 2,589,182 $ 5.73 3.77 $ 39,941,000 Options vested and expected to vest 2,848,713 $ 5.99 4.23 $ 43,219,000
SCHEDULE OF FAIR VALUE ASSUMPTIONS	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2023 Weighted-average fair value of options granted $ 10.58 Expected terms (in years) 5.50 6.11 Expected volatility 69 70 % Risk-free interest rate 3.64 3.76 % Dividend yield -
SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable at March 31, 2023: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.47 1.73 298,112 4.71 $ 1.72 298,112 $ 1.72 $ 2.23 2.60 309,068 3.61 $ 2.26 309,068 $ 2.26 $ 3.95 310,000 2.93 $ 3.95 310,000 $ 3.95 $ 4.08 6.30 409,850 5.66 $ 5.99 398,194 $ 6.00 $ 6.75 7.30 402,000 7.43 $ 7.18 279,500 $ 7.29 $ 7.37 7.79 260,323 5.13 $ 7.53 166,760 $ 7.50 $ 7.87 600,000 2.33 $ 7.87 600,000 $ 7.87 $ 7.89 12.38 274,173 2.57 $ 9.12 227,548 $ 8.84 $ 15.17 7,500 9.84 $ 15.17 - $ - $ 18.35 20,000 9.82 $ 18.35 - $ - $ 1.47 18.35 2,891,026 4.30 $ 6.03 2,589,182 $ 5.73
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY	A summary of the Company’s RSU activity (including performance stock units) and related information for the three months ended March 31, 2023 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY Number of RSUs Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2023 2,061,719 $ 6.88 RSUs granted - $ - RSUs vested (127,405 ) $ 7.34 RSUs cancelled/forfeited (75,000 ) $ 5.83 RSUs unvested - March 31, 2023 1,859,314 $ 6.82
SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS	The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS 2023 2022 For the Three Months Ended March 31, 2023 2022 Employees - selling, general and administrative $ 1,328,000 $ 1,676,000 Employees - R&D 163,000 186,000 Directors - selling, general and administrative 125,000 100,000 Consultants - R&D 17,000 54,000 Total $ 1,633,000 $ 2,016,000

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SCHEDULE OF SHARE BASED COMPENSATION	SCHEDULE OF SHARE BASED COMPENSATION Tranche Number of Shares Target Share Price Tranche 1 223,988 $25 Tranche 2 335,981 $35 Tranche 3 447,975 $45 Tranche 4 559,969 $50

DESCRIPTION OF BUSINESS AND B_2

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Consolidation basis description	entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights

SCHEDULE OF ACCOUNTS RECEIVABLE

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 73,000
Change in expected credit losses	20,000
Write-offs, net of recoveries	(11,000)
Ending balance	$ 82,000

SCHEDULE OF ESTIMATED FAIR VALU

SCHEDULE OF ESTIMATED FAIR VALUE (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Platform Operator, Crypto-Asset [Line Items]
Carrying value	$ 180,250,000
Fair Value, Inputs, Level 1 [Member] | 2026 Notes [Member]
Platform Operator, Crypto-Asset [Line Items]
Carrying value	72,628,000	$ 72,436,000
Fair value	73,590,000	71,550,000
Fair Value, Inputs, Level 1 [Member] | 2027 Notes [Member]
Platform Operator, Crypto-Asset [Line Items]
Carrying value	36,900,000	31,738,000
Fair value	40,250,000	35,112,000
Fair Value, Inputs, Level 1 [Member] | Oaktree Loan [Member]
Platform Operator, Crypto-Asset [Line Items]
Carrying value	59,322,000
Fair value	$ 65,000,000

SCHEDULE OF BASIC AND DILUTED E

SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounting Policies [Abstract]
Numerator – net loss	$ (6,643,000)	$ (2,438,000)
number of shares outstanding, basic and diluted	30,289,730	27,226,819
Net loss per share, basic and diluted	$ (0.22)	$ (0.09)

SCHEDULE OF INVESTMENT (Details

SCHEDULE OF INVESTMENT (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Melt Pharmaceuticals, Inc. [Member]
Schedule of Investments [Line Items]
Cost Basis	$ 19,310,000
Share of Equity Method Losses	(19,310,000)
Paid in Kind Interest	3,001,000
In Substance Capital Contributions	(3,001,000)
Net carrying value
Common Stock [Member] | Melt Pharmaceuticals, Inc. [Member]
Schedule of Investments [Line Items]
Cost Basis	5,810,000
Share of Equity Method Losses	(5,810,000)
Paid in Kind Interest
Common Stock [Member] | Surface Ophthalmics Inc [Member]
Schedule of Investments [Line Items]
Cost Basis	5,320,000
Share of Equity Method Losses	(5,320,000)
Net carrying value
Loan [Member] | Melt Pharmaceuticals, Inc. [Member]
Schedule of Investments [Line Items]
Cost Basis	13,500,000
Share of Equity Method Losses	(13,500,000)
Paid in Kind Interest	3,001,000
In Substance Capital Contributions	(3,001,000)
Net carrying value

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Jul. 31, 2021
Accounts Receivable, after Allowance for Credit Loss	$ 12,111,000			$ 82,000
Effective income tax rate	4.16%	0%
Federal income tax rate	21%	21%
Unrecognized tax benefits	$ 0			0
Eton Pharmaceuticals, Inc. [Member]
Investment owned, at fair value	$ 7,631,000			5,589,000
Investment owned balance shares	1,982,000
Ownership percentage	10%
Shares price	$ 3.85
Unrealized gain loss on investments	$ 2,042,000	$ 139,000
Melt Pharmaceuticals, Inc. [Member]
Investment owned balance shares	3,500,000
Ownership percentage	46%
Reduction in common stock investment	$ 0		$ 0
Investment interest rate	100%
Surface Ophthalmics Inc [Member]
Investment owned balance shares	3,500,000
Ownership percentage					20%
Reduction in common stock investment			$ 0
Restricted Stock Units (RSUs) [Member]
Number of shares vestted, RSUs	336,264	277,405
Stock Options, Unvested RSUs and Warrants [Member]
Antidilutive securities	4,750,340	5,546,200
Eton Pharmaceuticals, Inc. [Member]
Investment owned, at fair value	$ 7,631,000			$ 5,589,000

SCHEDULE OF DISAGGREGATED REVEN

SCHEDULE OF DISAGGREGATED REVENUE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 26,103,000	$ 22,120,000
Product Sales Net [Member]
Disaggregation of Revenue [Line Items]
Total revenues	20,453,000	20,340,000
Commissions Revenues [Member]
Disaggregation of Revenue [Line Items]
Total revenues		1,320,000
Transfer of Profit [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 5,650,000	$ 460,000

REVENUES (Details Narrative)

REVENUES (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract with customer liability current	$ 67,000	$ 113,000

RECENT PRODUCT ACQUISITIONS, _2

RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Jan. 31, 2023	Oct. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable			$ 12,111,000	$ 6,249,000
Asset Purchase Agreement [Member]
Proceeds from related party		$ 6,000,000
Milestones receivable based on agreed revenues		$ 4,500,000
RPC Agreement [Member]
Cash			226,000	579,000
RPC Agreement [Member] | Cash [Member]
Accounts receivable			116,000	128,000
Transition Services Agreement [Member]
Due from reimbursement of services amount			162,000	254,000
Accrued expenses			307,000	$ 453,000
Other income			124,000
Loss on sale of assets			$ 94,800
One Time Payment [Member]
Milestone payment	$ 130,000,000
Costs incurred	558,000
Purchase price acquisition	130,558,000
One Time Payment [Member] | Maximum [Member]
Milestone payment	$ 45,000,000

SCHEDULE OF CONDENSED INCOME ST

SCHEDULE OF CONDENSED INCOME STATEMENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues, net	$ 26,103,000	$ 22,120,000
Loss from operations	1,210,000	2,101,000
Net loss	(6,643,000)	(2,438,000)
Melt Pharmaceuticals, Inc. [Member]
Revenues, net
Loss from operations	(1,858,000)	(3,337,000)
Net loss	$ (1,858,000)	$ (3,337,000)

SCHEDULE OF CONDENSED BALANCE S

SCHEDULE OF CONDENSED BALANCE SHEET (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets	$ 51,687,000	$ 118,260,000
Total assets	217,498,000	157,378,000
Total liabilities	195,970,000	130,138,000
Total preferred stock and stockholders’ deficit	21,883,000	27,595,000
Total liabilities and stockholders’ equity	217,498,000	157,378,000
Melt Pharmaceuticals, Inc. [Member]
Current assets	133,000	655,000
Non-current assets	133,000	107,000
Total assets	266,000	762,000
Total liabilities	20,273,000	19,056,000
Total preferred stock and stockholders’ deficit	(20,007,000)	(18,294,000)
Total liabilities and stockholders’ equity	$ 266,000	$ 762,000

INVESTMENT IN, AND NOTE RECEI_3

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Apr. 30, 2022	Feb. 28, 2019	Mar. 31, 2023	Dec. 31, 2022	Sep. 01, 2021
Due from related parties			$ 198,000	$ 139,000
Rreimbursable expenses			908,000
Melt Loan Agreement [Member]
Loan amount					$ 13,500,000
Debt instrument interest rate stated percentage					12.50%
Increase in interest rate	3%
Melt Loan Agreement [Member] | Third Party Investor [Member]
Loan amount	$ 10,000,000
Melt Pharmaceuticals, Inc. [Member]
Reimbursable expenses			59,000
Melt Pharmaceuticals, Inc. [Member] | Management Services Agreement [Member]
Administrative fees expense		$ 10,000
Melt Pharmaceuticals, Inc. [Member] | Management Services Agreement [Member] | Related Party [Member]
Due from related parties			198,000	139,000
Melt Pharmaceuticals, Inc. [Member] | Melt Loan Agreement [Member]
Notes receivable related parties			$ 16,501,000	$ 15,984,000

SUMMARY OF CONDENSED INCOME STA

SUMMARY OF CONDENSED INCOME STATEMENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues, net	$ 26,103,000	$ 22,120,000
Loss from operations	1,210,000	2,101,000
Net loss	(6,643,000)	(2,438,000)
Surface Pharmaceuticals Inc [Member]
Revenues, net
Loss from operations	(1,587,000)	(1,996,000)
Net loss	$ (1,524,000)	$ 1,996,000

SUMMARY OF CONDENSED BALANCE SH

SUMMARY OF CONDENSED BALANCE SHEET (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets	$ 51,687,000	$ 118,260,000
Total assets	217,498,000	157,378,000
Total liabilities	195,970,000	130,138,000
Total preferred stock and stockholders’ deficit	21,883,000	27,595,000
Total liabilities and stockholders’ equity	217,498,000	157,378,000
Surface Pharmaceuticals Inc [Member]
Current assets	13,350,000	15,350,000
Non-current assets	902,000	652,000
Total assets	14,252,000	16,002,000
Total liabilities	995,000	1,586,000
Total preferred stock and stockholders’ deficit	13,257,000	14,416,000
Total liabilities and stockholders’ equity	$ 14,252,000	$ 16,002,000

INVESTMENT IN SURFACE OPHTHAL_3

INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)	Mar. 31, 2023 shares
Surface Pharmaceuticals Inc [Member]
investment owned shares	3,500,000

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 5,023,000	$ 3,707,000
Work in progress	36,000	38,000
Finished goods	4,034,000	2,796,000
Total inventories	$ 9,093,000	$ 6,541,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 527,000	$ 858,000
Prepaid computer software licenses and related expenses	1,072,000	1,165,000
Due from Melt Pharmaceuticals	198,000	139,000
Other prepaid expenses	1,689,000	1,331,000
Deposits and other current assets	118,000	118,000
Total prepaid expenses and other current assets	$ 3,604,000	$ 3,611,000

SCHEDULE OF PROPERTY, PLANT AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Computer hardware	$ 1,060,000	$ 979,000
Furniture and equipment	922,000	860,000
Lab and pharmacy equipment	4,335,000	4,259,000
Leasehold improvements	6,555,000	6,449,000
Property, plant and equipment, gross	12,872,000	12,547,000
Accumulated depreciation	(9,286,000)	(9,061,000)
Property, plant and equipment, net	$ 3,586,000	$ 3,486,000

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 225,000	$ 376,000

SCHEDULE OF FINITE LIVED INTANG

SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	$ 1,574,000	$ 1,572,000
Accumulated amortization	(860,000)	(793,000)
Capitalized internal-use software in process	1,563,000	1,333,000
Total finite lived intangible assets net	2,277,000	2,112,000
Capitalized Internal Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	1,415,000	1,413,000
Third Party Software License [Member]
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	$ 159,000	$ 159,000

CAPITALIZED SOFTWARE DEVELOPM_3

CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Capitalized Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expenses	$ 67,000	$ 43,000

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Cost	$ 156,270,000
Accumulated amortization	(4,278,000)
Impairment
Net Carrying value	151,992,000	$ 23,725,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	981,000
Accumulated amortization	(183,000)
Impairment
Net Carrying value	$ 798,000
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
Cost	$ 100,000
Accumulated amortization	(25,000)
Impairment
Net Carrying value	75,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	267,000
Accumulated amortization
Impairment
Net Carrying value	$ 267,000
Useful life, description	Indefinite
New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 154,193,000
Accumulated amortization	(3,533,000)
Impairment
Net Carrying value	150,660,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	596,000
Accumulated amortization	(475,000)
Impairment
Net Carrying value	$ 121,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Cost	$ 75,000
Accumulated amortization	(5,000)
Impairment
Net Carrying value	70,000
Non-Competition Clause [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	50,000
Accumulated amortization	(50,000)
Impairment
Net Carrying value
State Pharmacy Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	25 years
Cost	$ 8,000
Accumulated amortization	(7,000)
Impairment
Net Carrying value	$ 1,000
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	7 years
Minimum [Member] | New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years
Minimum [Member] | Non-Competition Clause [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	19 years
Maximum [Member] | New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	15 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	15 years
Maximum [Member] | Non-Competition Clause [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	4 years

SCHEDULE OF AMORTIZATION EXPENS

SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 2,207,000	$ 404,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	22,000	22,000
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	2,000	8,000
New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	2,170,000	341,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 13,000	$ 33,000

SCHEDULE OF ESTIMATED FUTURE AM

SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 8,777,000
2024	11,673,000
2025	11,652,000
2026	11,652,000
2027	11,652,000
Thereafter	96,319,000
Intangible assets	$ 151,725,000

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 6,237,000	$ 6,440,000
Accrued insurance premium	237,000	575,000
Accrued IHEEZO milestone payment (see Note 16)	5,000,000	5,000,000
Accrued RPC transition payments (see Note 4)	307,000	453,000
Accrued litigation settlements	49,000	49,000
Accrued exit fee for note payable (see Note 13)	2,275,000
Accrued interest	1,964,000	1,254,000
Total accounts payable and accrued expenses	16,069,000	13,771,000
Less: Current portion	(13,794,000)	(13,771,000)
Non-current total accrued expenses	$ 2,275,000

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) - Financing Agreement [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument interest rate, during period	4.13%
Accrued monthly payments	$ 114,000

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Remainder of 2023	$ 14,145,000
2024	18,695,000
2025	18,695,000
2026	147,325,000
2027	45,030,000
Total minimum payments	243,890,000
Less: amount representing interest payments	(63,640,000)
Notes payable, gross	180,250,000
Less: unamortized discount, net of premium	(11,400,000)
Notes payable, net of unamortized discount	$ 168,850,000	$ 104,174,000

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)			1 Months Ended				3 Months Ended
	Jan. 19, 2023	Dec. 14, 2022	Mar. 31, 2023	Jun. 30, 2021	May 31, 2021	Apr. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Jan. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt principal amount							$ 761,000	$ 193,000
Oaktree Loan [Member]
Debt Instrument [Line Items]
Debt principal amount							12,000
Debt principal amount							95,000
11.875% Senior Notes Due 2027 [Member]
Debt Instrument [Line Items]
Debt principal amount			$ 950,000				950,000		$ 5,250,000	$ 35,000,000
Proceeds from issuance of debt							$ 36,699,000
Debt instrument maturity date							Dec. 31, 2027
Interest rate, during period							1,187.50%
Debt principal amount							$ 200,000
Debt principal amount							$ 1,395,000
Interest rate									11.875%
Shares issued price per share			$ 25				$ 25
Deducting underwriting discounts and commissions and expenses			$ 3,551,000				$ 3,551,000
Redemption description							redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2027 Notes for cash in whole or in part at any time at its option (i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note
8.625% Senior Notes Due 2026 [Member]
Debt Instrument [Line Items]
Debt principal amount						$ 50,000,000
Debt instrument increase decrease for period net					$ 5,000,000
Debt instrument maturity date						Apr. 30, 2026
Interest rate, during period						8.625%
Debt principal amount							$ 193,000	193,000
Debt principal amount							1,810,000	$ 1,810,000
Deducting underwriting discounts and commissions and expenses				$ 1,158,000
Redemption description						redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed
Debt instrument unamortized premium				322,000
8.625% Senior Notes Due 2026 [Member] | Investor [Member]
Debt Instrument [Line Items]
Debt instrument increase decrease for period net				20,000,000
Proceeds from issuance of debt				$ 19,164,000		$ 51,909,000
Shares issued price per share				$ 25.75		$ 25
Deducting underwriting discounts and commissions and expenses						$ 3,091,000
Interest expense debt				$ 278,000
Credit and Guaranty Agreement [Member] | Oaktree Fund Administration LLC [Member]
Debt Instrument [Line Items]
Debt principal amount			$ 65,000,000				65,000,000
Proceeds from issuance of debt							$ 30,000,000
Debt instrument maturity date	Jan. 19, 2026
Interest rate, during period							1,139.80%
Fees and offering expenses							$ 915,000
Original debt discount							$ 2,500,000
Interest rate			3.50%				3.50%
Stock issued							$ 2,275,000
Debt principal amount							$ 5,690,000
Warrants to purchase shares			750,000				750,000
Credit and Guaranty Agreement [Member] | Oaktree Fund Administration LLC [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Warrants to purchase shares			375,000				375,000
Credit and Guaranty Agreement [Member] | Oaktree Fund Administration LLC [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Interest rate, during period							650%
Credit and Guaranty Agreement [Member] | Oaktree Fund Administration LLC [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument increase decrease for period net							$ 35,000,000
Credit and Guaranty Agreement [Member] | Oaktree Fund Administration LLC [Member] | Senior Secured Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt principal amount			$ 100,000,000				100,000,000
Loan and Security Agreement [Member] | BR Loan [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 100,000,000							$ 59,750,000
Debt instrument maturity date		Dec. 14, 2025
Interest rate		3%
Debt principal amount							356,000
Debt principal amount							1,565,000
Interest rate		10.875%
Proceeds from loans receivable			$ 1,200,000
Debt principal amount							$ 5,465,000

SCHEDULE OF FUTURE LEASE PAYMEN

SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Leases
Remainder of 2023	$ 925,000
2024	1,262,000
2025	1,093,000
2026	1,114,000
2027	972,000
Thereafter	5,829,000
Total minimum lease payments	11,195,000
Less: amount representing interest payments	(3,314,000)
Total operating lease liabilities	7,881,000
Less: current portion, operating lease liabilities	(744,000)	$ (723,000)
Operating lease liabilities, net of current portion	$ 7,137,000	$ 7,332,000

LEASES (Details Narrative)

LEASES (Details Narrative)	3 Months Ended
	Mar. 31, 2023 USD ($) ft²	Mar. 31, 2022 USD ($)
Weighted average discount rate percent	6.61%
Lease term	10 years 8 months 19 days
Operating lease payments | $	$ 306,000	$ 166,000
Operating lease expense | $	$ 309,000	$ 238,000
Carlsbad [Member]
Area of land	5,789
Lease expiration date, description	March 2025
Ledgewood [Member]
Area of land	35,326
Lease expiration date, description	July 2026
Area of land	1,400
Ledgewood [Member] | Lease Amendment [Member]
Area of land	8,900
Nashville [Member]
Area of land	5,500
Lease expiration date, description	November 30, 2024
Nashville 1 [Member]
Area of land	11,552
Lease expiration date, description	June 2027
Minimum [Member] | Office and Laboratory Space [Member]
Lease term	1 year
Maximum [Member] | Office and Laboratory Space [Member]
Lease term	5 years

SCHEDULE OF STOCK OPTION PLAN A

SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details) - Stock Option Plan [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, outstanding, beginning balance | shares	3,027,701
Weighted average exercise price, outstanding, beginning balance | $ / shares	$ 5.90
Number of shares, options granted | shares	28,500
Weighted average exercise price, options granted | $ / shares	$ 17.40
Number of shares, options exercised | shares	(123,063)
Weighted average exercise price, options exercised | $ / shares	$ 5.54
Number of shares, options cancelled/forfeited | shares	(42,112)
Weighted average exercise price, options cancelled/forfeited | $ / shares	$ 5.61
Number of shares, outstanding, ending balance | shares	2,891,026
Weighted average exercise price, outstanding, ending balance | $ / shares	$ 6.03
Weighted average. remaining contractual life, options outstanding	4 years 3 months 18 days
Aggregate intrinsic value, options outstanding | $	$ 43,730,000
Number of shares, options exercisable | shares	2,589,182
Weighted average exercise price, options exercisable | $ / shares	$ 5.73
Weighted average. remaining contractual life, options exercisable	3 years 9 months 7 days
Aggregate intrinsic value, options exercisable | $	$ 39,941,000
Number of shares, options vested and expected to vest | shares	2,848,713
Weighted average exercise price, options vested and expected to vest | $ / shares	$ 5.99
Weighted average. remaining contractual life, options vested and expected to vest	4 years 2 months 23 days
Aggregate intrinsic value, options vested and expected to vest | $	$ 43,219,000

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - Options Granted to Employees [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average fair value of options granted	$ 10.58
Dividend yield
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected terms (in years)	5 years 6 months
Expected volatility	69%
Risk-free interest rate	3.64%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected terms (in years)	6 years 1 month 9 days
Expected volatility	70%
Risk-free interest rate	3.76%

SCHEDULE OF STOCK OPTION OUTSTA

SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1.47
Range of Exercise Prices, maximum	$ 18.35
Number of Options Outstanding | shares	2,891,026
Weighted Average Remaining Contractual Life in Years	4 years 3 months 18 days
Weighted Average Exercise Price	$ 6.03
Number Exercisable | shares	2,589,182
Weighted Average Exercisable Exercise Price	$ 5.73
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	1.47
Range of Exercise Prices, maximum	$ 1.73
Number of Options Outstanding | shares	298,112
Weighted Average Remaining Contractual Life in Years	4 years 8 months 15 days
Weighted Average Exercise Price	$ 1.72
Number Exercisable | shares	298,112
Weighted Average Exercisable Exercise Price	$ 1.72
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	2.23
Range of Exercise Prices, maximum	$ 2.60
Number of Options Outstanding | shares	309,068
Weighted Average Remaining Contractual Life in Years	3 years 7 months 9 days
Weighted Average Exercise Price	$ 2.26
Number Exercisable | shares	309,068
Weighted Average Exercisable Exercise Price	$ 2.26
Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 3.95
Number of Options Outstanding | shares	310,000
Weighted Average Remaining Contractual Life in Years	2 years 11 months 4 days
Weighted Average Exercise Price	$ 3.95
Number Exercisable | shares	310,000
Weighted Average Exercisable Exercise Price	$ 3.95
Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	4.08
Range of Exercise Prices, maximum	$ 6.30
Number of Options Outstanding | shares	409,850
Weighted Average Remaining Contractual Life in Years	5 years 7 months 28 days
Weighted Average Exercise Price	$ 5.99
Number Exercisable | shares	398,194
Weighted Average Exercisable Exercise Price	$ 6
Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	6.75
Range of Exercise Prices, maximum	$ 7.30
Number of Options Outstanding | shares	402,000
Weighted Average Remaining Contractual Life in Years	7 years 5 months 4 days
Weighted Average Exercise Price	$ 7.18
Number Exercisable | shares	279,500
Weighted Average Exercisable Exercise Price	$ 7.29
Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	7.37
Range of Exercise Prices, maximum	$ 7.79
Number of Options Outstanding | shares	260,323
Weighted Average Remaining Contractual Life in Years	5 years 1 month 17 days
Weighted Average Exercise Price	$ 7.53
Number Exercisable | shares	166,760
Weighted Average Exercisable Exercise Price	$ 7.50
Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 7.87
Number of Options Outstanding | shares	600,000
Weighted Average Remaining Contractual Life in Years	2 years 3 months 29 days
Weighted Average Exercise Price	$ 7.87
Number Exercisable | shares	600,000
Weighted Average Exercisable Exercise Price	$ 7.87
Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	7.89
Range of Exercise Prices, maximum	$ 12.38
Number of Options Outstanding | shares	274,173
Weighted Average Remaining Contractual Life in Years	2 years 6 months 25 days
Weighted Average Exercise Price	$ 9.12
Number Exercisable | shares	227,548
Weighted Average Exercisable Exercise Price	$ 8.84
Range Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 15.17
Number of Options Outstanding | shares	7,500
Weighted Average Remaining Contractual Life in Years	9 years 10 months 2 days
Weighted Average Exercise Price	$ 15.17
Number Exercisable | shares
Weighted Average Exercisable Exercise Price
Range Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 18.35
Number of Options Outstanding | shares	20,000
Weighted Average Remaining Contractual Life in Years	9 years 9 months 25 days
Weighted Average Exercise Price	$ 18.35
Number Exercisable | shares
Weighted Average Exercisable Exercise Price

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of RSUs unvested, outstanding, beginning balance | shares	2,061,719
Weighted average grant date fair value, beginning balance | $ / shares	$ 6.88
Number of RSUs granted | shares
Weighted average grant date fair value, RSUs granted | $ / shares
Number of RSUs vested | shares	(127,405)
Weighted average grant date fair value, RSUs vested | $ / shares	$ 7.34
Number of RSUs cancelled/forfeited | shares	(75,000)
Weighted average grant date fair value, RSUs cancelled/forfeited | $ / shares	$ 5.83
Number of RSUs unvested, outstanding, ending balance | shares	1,859,314
Weighted average grant date fair value, ending balance | $ / shares	$ 6.82

SCHEDULE OF STOCK BASED COMPENS

SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total	$ 1,633,000	$ 2,016,000
Employees [Member] | Selling, General and Administrative Expenses [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total	1,328,000	1,676,000
Employees [Member] | Research and Development Expense [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total	163,000	186,000
Director [Member] | Selling, General and Administrative Expenses [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total	125,000	100,000
Consultant [Member] | Research and Development Expense [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total	$ 17,000	$ 54,000

STOCKHOLDERS_ EQUITY AND STOC_3

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of option, shares		$ 148,000	$ 4,000
Proceeds from stock option exercise		148,000	4,000
Common stock withheld for payroll tax withholdings, value		(850,000)	(777,000)
Stock-based compensation		$ 1,633,000	2,016,000
2017 Incentive Stock and Awards Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares available for future issuances		2,145,767
Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Forfeiture factor rate		10%
Andrew R Boll [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares isssued		23,000
Number of common stock issued	13,398
Number of stock withheld for payroll tax purposes	9,602
Common stock withheld for payroll tax withholdings, value	$ 142,000
Mark L. Baum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares isssued		88,000
Number of common stock issued	52,821
Number of stock withheld for payroll tax purposes	35,179
Common stock withheld for payroll tax withholdings, value	$ 519,000
Mr Boll [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cashless exercise of options, shares		90,000
Number of common stock issued		55,558
Number of common stock issued		$ 6
Common stock withheld for payroll tax withholdings, shares		8,921
Common stock withheld for payroll tax withholdings, value		$ 189,000
Maximum [Member] | 2017 Incentive Stock and Awards Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized		6,000,000
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares isssued
Stock Option Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Closing price of common stock price per share		$ 21.16
Expense expected to recognize over the weighted-average remaining vesting period		$ 1,441,000
Expense expected to recognize over the weighted-average remaining vesting period		3 years
Stock-based compensation		$ 341,000	272,000
Intrinsic value of options exercised		$ 1,819,000
Stock Option Plan [Member] | Employees and Consultant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting term description		Vesting terms for options granted to employees during the three months ended March 31, 2023 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years.
Unvested RSUs [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expense expected to recognize over the weighted-average remaining vesting period		$ 2,476,000
Expense expected to recognize over the weighted-average remaining vesting period		4 months 24 days
Stock-based compensation		$ 1,292,000	1,744,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of option, shares
Number of stock withheld for payroll tax purposes		53,702	96,622
Common stock withheld for payroll tax withholdings, value			$ (1,000)
Common Stock [Member] | Mr Boll [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cashless exercise of options, shares		25,521
Common Stock [Member] | Options Held [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of option, shares		$ 33,063
Proceeds from stock option exercise		$ 148,000
Cashless exercise of options, shares		33,063
Common Stock [Member] | Options Held [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price		$ 3.50
Common Stock [Member] | Options Held [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price		$ 7.60
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares isssued		16,405

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Aug. 31, 2021	Jul. 31, 2021	Dec. 31, 2019	Apr. 30, 2017	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase of intangible asset included in accounts payable and accrued expenses					$ 5,000,000		$ 5,000,000
Klarity License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense					75,000	$ 71,000
Milestone payment in cash					71,000	30,000
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment description				Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Initial Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense				$ 50,000
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Second Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense				50,000
Net sales				50,000
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Final Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense				50,000
Net sales				$ 100,000
Injectable Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense					8,000	7,000
Milestone payment in cash					9,000	8,000
Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment description			Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold
Initial milestone payment			$ 33,000
Asset Purchase, License and Related Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense					$ 293,000	213,000
Sintetica Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for royalties		$ 18,000,000
Sintetica Agreement [Member] | Due Within Thirty Days [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for royalties		$ 5,000,000
Wakamoto Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for royalties	$ 2,000,000
Commercial payments for royalties	$ 6,200,000
Dexycu Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commission revenues						1,320,000
Sales and Marketing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Description for commission payments					Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts
Commission expenses					$ 130,000	$ 1,047,000

SEGMENTS AND CONCENTRATIONS (De

SEGMENTS AND CONCENTRATIONS (Details Narrative)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Three Main Suppliers [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	90%	74%
Two Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	36%	32%

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION (Details) - Subsequent Event [Member]	Apr. 30, 2023 $ / shares shares
Share-Based Payment Arrangement, Tranche One [Member]
Subsequent Event [Line Items]
Number of shares | shares	223,988
Target share price | $ / shares	$ 25
Share-Based Payment Arrangement, Tranche Two [Member]
Subsequent Event [Line Items]
Number of shares | shares	335,981
Target share price | $ / shares	$ 35
Share-Based Payment Arrangement, Tranche Three [Member]
Subsequent Event [Line Items]
Number of shares | shares	447,975
Target share price | $ / shares	$ 45
Share Based Compensation Award Tranche Four [Member]
Subsequent Event [Line Items]
Number of shares | shares	559,969
Target share price | $ / shares	$ 50

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Apr. 30, 2023	Apr. 30, 2023	Jan. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Subsequent Event [Line Items]
Common stock withheld for payroll tax withholdings, value				$ (850,000)	$ (777,000)
Common Stock [Member]
Subsequent Event [Line Items]
Common stock withheld for payroll tax withholdings, shares				53,702	96,622
Common stock withheld for payroll tax withholdings, value					$ (1,000)
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Target share price	$ 25	$ 25
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Target share price	$ 50	$ 50
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Cashless exercise of warrants to purchase to common stock	3,260	3,260
Subsequent Event [Member] | Common Stock [Member] | Minimum [Member]
Subsequent Event [Line Items]
Warrants exercise price	$ 1.70	$ 1.70
Subsequent Event [Member] | Common Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Warrants exercise price	$ 7.52	$ 7.52
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of granted, sharess		3,260
Mark L. Baum [Member]
Subsequent Event [Line Items]
Number of granted, sharess			52,821
Common stock withheld for payroll tax withholdings, shares			35,179
Common stock withheld for payroll tax withholdings, value			$ 519,000
Mark L. Baum [Member] | Subsequent Event [Member] | Performance Stock Units [Member]
Subsequent Event [Line Items]
Number of granted, sharess		1,567,913
Mark L. Baum [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of granted, sharess		77,167
Cashless exercise of warrants to purchase to common stock	180,000	180,000
Warrants exercise price	$ 8.99	$ 8.99
Common stock withheld for payroll tax withholdings, shares		40,466
Common stock withheld for payroll tax withholdings, value	$ 849,000
Mark L. Baum [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of granted, sharess		62,367